Chronic Leukemia Perspective

 
 
  • ESMO Guideline for Mantle Cell Lymphoma ESMO recently published its guideline for mantle cell lymphoma. Author Martin Dreyling highlights some of the key, evidence-based recommendations.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • CLL's 'Very Unusual Year'   Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.
  • Ibrutinib Stands Center Stage in CLL   Dr. John Gribben highlights new data on single and combination therapies for CLL as presented at EHA 2014.
  • Ibrutinib Results RESONATE in Refractory CLL   Drs. Bruce Cheson and Myron Czuczman discuss lymphoma and leukemia highlights from ASCO 2014, including the RESONATE and SEXIE trials and emerging antibody-drug conjugates.
  • ASCO® 2014: Aiming at Cancer’s Achilles Heel   Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • Mantle Cell Lymphoma -- Still More Questions Than Answers Mantle cell lymphoma remains a clinical challenge. Dr. Julie Vose discusses current evidence on treatments, differences in strategy, and whether emerging novel therapies could improve outcomes.
  • FDA Sends Valentine to CLL Patients   The FDA approval of ibrutinib is a red-letter day for patients with relapsed chronic lymphocytic leukemia, because of the drug’s quick action and effectiveness, says Dr. Bruce Cheson.
  • Idelalisib Combo Rings Bells in Relapsed CLL   Patients with relapsed chronic lymphocytic leukemia, who were less able to undergo chemotherapy, had improved OS with a combination of idelalisib and rituximab, in a study reported by Dr Bruce Cheson.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Novel Agents: Making the Benefit Last in CLL Drs. Susan O'Brien and Bruce Cheson discuss the exciting array of oral, well-tolerated, quick-acting therapies for CLL that provide durable if only partial remission.
  • Tailoring CLL Treatment to a TTT In CLL, combinations and sequences of agents are tailored to initial tumor load and response to therapy to optimize outcome, says Dr. Michael Hallek in a Medscape interview from ASH 2013.
  • CLL Combos: And the Winner Is… The question of which is better -- FRC or BR -- is settled, sort of, at ASH 2013, in a study discussed by Drs. Bruce Cheson and Clemens Wendtner.
  • ASH 2013: Big Year for CLL, Lymphoma   Highlighting major studies and a plethora of new drugs, Dr. Bruce Cheson predicts that ASH 2013 will be a big year for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
  • Lenalidomide Trial KO'd: A Blow to CLL Patients?   Dr. Bruce Cheson discusses the clinical ramifications of the decision to halt the ORIGIN trial, which compared lenalidomide vs chlorambucil in previously untreated elderly patients with CLL.
  • Abandoning PETs in Lymphoma   Drs. Bruce Cheson and Gilles Salles discuss lymphoma highlights from ASCO 2013 on new targeted agents, potential combinations, and indications that surveillance requires few scans.
  • Blood's Up -- and So Are the Outcomes   Dr. Bruce Cheson highlights noteworthy studies in lymphoma, chronic lymphocytic leukemia, and multiple myeloma being presented at ASCO 2013.
  • New Therapy Unleashes 'Serial Killer' Cells in Leukemia Adoptive immunotherapy is providing exciting preliminary results in leukemia patients. Leading researcher Dr. Carl June explains the therapy and its potential application to other cancers.
  • ASH 2012: More Fuel for the Fire   Dr. Bruce Cheson highlights studies that should prove controversial and practice-changing, as well as new drugs that expand treatment options.